We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+19.79%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$358M
AUM Growth
+$121M
Cap. Flow
+$99.3M
Cap. Flow %
27.73%
Top 10 Hldgs %
55.61%
Holding
85
New
30
Increased
11
Reduced
11
Closed
21

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$13.4M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$10.5M
3
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$6.12M
4
SWTX
SpringWorks Therapeutics
SWTX
+$5.02M
5
AZN icon
AstraZeneca
AZN
+$4.12M

Top Sells

Rank Stock Value
1
NARI
Inari Medical, Inc. Common Stock
NARI
+$7.61M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$5.98M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$5.69M
4
RPTX
Repare Therapeutics
RPTX
+$4.49M
5
KURA icon
Kura Oncology
KURA
+$3.89M

Sector Composition

Rank Sector Weight
1 Healthcare 51.05%
2 Financials 0.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VKTX icon
51
Viking Therapeutics
VKTX
$4.11B
$680K 0.19%
+250,000
New +$819K
ISEE
52
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$538K 0.15%
+30,000
New +$394K
IMTXW
53
DELISTED
Immatics N.V. Warrants
IMTXW
$507K 0.14%
187,204
– –
KURA icon
54
PUT
Kura Oncology
KURA
$928M
$507K 0.14%
+37,100
New +$572K
RCOR
55
DELISTED
Renovacor, Inc.
RCOR
$503K 0.14%
199,490
– –
TNGX icon
56
Tango Therapeutics
TNGX
$4.47B
$297K 0.08%
+81,982
New +$350K
SCLXW icon
57
Scilex Holding Co Warrant
SCLXW
$2.74M
$17K ﹤0.01%
+100,000
New +$18.8K
RCOR.WS
58
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
$6K ﹤0.01%
75,000
– –
MSACW
59
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$3K ﹤0.01%
33,333
– –
CELU icon
60
PUT
Celularity
CELU
$22M
– –
-18,360
Closed -$624K
CLDX icon
61
CALL
Celldex Therapeutics
CLDX
$2.78B
– –
-145,000
Closed -$3.91M
CRIS icon
62
Curis
CRIS
$9.1M
– –
-851
Closed -$335K
CRSP icon
63
CALL
CRISPR Therapeutics
CRSP
$4.68B
– –
-70,000
Closed -$4.25M
ESTA icon
64
PUT
Establishment Labs
ESTA
$2.68B
– –
-150,000
Closed -$8.16M
FATE icon
65
CALL
Fate Therapeutics
FATE
$294M
– –
-67,500
Closed -$1.67M
IOVA icon
66
CALL
Iovance Biotherapeutics
IOVA
$2.29B
– –
-150,000
Closed -$1.66M
LEGN icon
67
CALL
Legend Biotech
LEGN
$4.55B
– –
-50,000
Closed -$2.75M
LLY icon
68
CALL
Eli Lilly
LLY
$1.06T
– –
-30,000
Closed -$9.73M
MRNA icon
69
CALL
Moderna
MRNA
$22.6B
– –
-15,000
Closed -$2.14M
NVAX icon
70
CALL
Novavax
NVAX
$1.29B
– –
-85,000
Closed -$4.37M
NVAX icon
71
PUT
Novavax
NVAX
$1.29B
– –
-90,000
Closed -$4.63M
LNAI
72
PUT
Lunai Bioworks
LNAI
$10.5M
– –
-2,500
Closed -$386K
RPTX
73
DELISTED
Repare Therapeutics
RPTX
– –
-321,200
Closed -$4.49M
SPRY icon
74
ARS Pharmaceuticals
SPRY
$596M
– –
-170,000
Closed -$721K
TERN
75
DELISTED
Terns Pharmaceuticals
TERN
– –
-401,268
Closed -$995K
1 2
3
4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return

Affinity Asset Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Affinity Asset Advisors held 85 positions worth $358M, up 51% from $237M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Affinity Asset Advisors deployed $99.3M of net new capital in Q3 2022, opening 30 new positions and adding to 11 existing holdings. Its largest new stake was Sanofi: 300,000 shares worth $11.4M.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 64% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Inari Medical, Inc. Common Stock, an estimated $7.61M trimmed.

  • Affinity Asset Advisors's largest Q3 2022 buy was Sanofi: 300,000 shares worth $11.4M.
  • Affinity Asset Advisors added most to POINT Biopharma Global Inc. Common Stock in Q3 2022, an estimated $6.12M increase.
  • Affinity Asset Advisors's biggest Q3 2022 reduction was Inari Medical, Inc. Common Stock, cutting an estimated $7.61M.
  • Affinity Asset Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, selling an estimated $5.98M.
  • Affinity Asset Advisors's ten largest holdings make up 56% of its $358M portfolio in Q3 2022.
  • Affinity Asset Advisors opened 30 new positions and closed 21 in Q3 2022.
  • Affinity Asset Advisors's portfolio value rose 51% quarter-over-quarter to $358M.

Based on Affinity Asset Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.